1. Home
  2. BNR vs HHS Comparison

BNR vs HHS Comparison

Compare BNR & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNR
  • HHS
  • Stock Information
  • Founded
  • BNR 2014
  • HHS 1923
  • Country
  • BNR China
  • HHS United States
  • Employees
  • BNR N/A
  • HHS N/A
  • Industry
  • BNR Medical Specialities
  • HHS Advertising
  • Sector
  • BNR Health Care
  • HHS Consumer Discretionary
  • Exchange
  • BNR Nasdaq
  • HHS Nasdaq
  • Market Cap
  • BNR 29.1M
  • HHS 30.3M
  • IPO Year
  • BNR 2020
  • HHS N/A
  • Fundamental
  • Price
  • BNR $3.16
  • HHS $4.00
  • Analyst Decision
  • BNR
  • HHS
  • Analyst Count
  • BNR 0
  • HHS 0
  • Target Price
  • BNR N/A
  • HHS N/A
  • AVG Volume (30 Days)
  • BNR 38.8K
  • HHS 30.4K
  • Earning Date
  • BNR 06-06-2025
  • HHS 08-07-2025
  • Dividend Yield
  • BNR N/A
  • HHS N/A
  • EPS Growth
  • BNR N/A
  • HHS N/A
  • EPS
  • BNR N/A
  • HHS N/A
  • Revenue
  • BNR $72,112,038.00
  • HHS $181,355,000.00
  • Revenue This Year
  • BNR $136.32
  • HHS $6.54
  • Revenue Next Year
  • BNR N/A
  • HHS N/A
  • P/E Ratio
  • BNR N/A
  • HHS N/A
  • Revenue Growth
  • BNR 0.53
  • HHS N/A
  • 52 Week Low
  • BNR $2.18
  • HHS $3.24
  • 52 Week High
  • BNR $7.90
  • HHS $8.87
  • Technical
  • Relative Strength Index (RSI)
  • BNR 48.34
  • HHS 44.31
  • Support Level
  • BNR $3.06
  • HHS $3.24
  • Resistance Level
  • BNR $3.50
  • HHS $4.14
  • Average True Range (ATR)
  • BNR 0.36
  • HHS 0.46
  • MACD
  • BNR -0.04
  • HHS -0.00
  • Stochastic Oscillator
  • BNR 20.16
  • HHS 34.42

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

Share on Social Networks: